The specific goal for this meeting is to foster fruitful and creative interactions between researchers interested in applying these systems to genome engineering and related advances in a wide variety of organisms, together with scientists studying the basic biology of CRISPR-Cas and related bacterial defense systems.
All are welcome to register and join the 2022 DOE Joint Genome Institute (JGI) Genomics of Energy & Environment Meeting, which coincides with our 25th Anniversary. The JGI convenes this annual gathering of leaders from diverse disciplines to highlight how they are addressing the world’s most pressing energy and environmental challenges. Many of these presenters have been supported by the research infrastructure – DNA sequencing, synthesis, metabolomics, data analysis, and new technology developments – that the JGI offers through its User Programs on a competitive, peer-reviewed basis to the worldwide scientific community. This year’s Meeting, to be held August 29 – 31, will be a hybrid event – in person at Lawrence Berkeley National Laboratory (Berkeley Lab) – and virtually through the Social27 platform.
This year we are bringing the event back to be more commercially and strategically focused, where in an intimate setting attendees will have the opportunity to connect with the full cell & gene community, enabling a 360-degree view on the current landscape. Â
It’s the destination for those wanting to debate the challenges, explore the opportunities, and discover the latest innovations, all within Europe and the UK.Â
In a bespoke setting, attendees will have access to the complete European advanced therapies landscape from macro to micro.Â
It’s the only event to offer companies a credible platform to position their company and solutions as leading providers in the advanced therapies technology and services space, including being able to place their brand directly under the nose of key decision makers from across Europe and the UK.
Hosted in London the event is positioned front and center of all the action within the European advanced therapies landscape.
Each year, Global Genes convenes one of the world’s largest gatherings of rare disease patients, caregivers, advocates, healthcare professionals, researchers, partners, and allies at the RARE Patient Advocacy Summit.
This year we’re celebrating being back together again, and have opportunities for you to join us in person or online for two days of connection opportunities, educational sessions, fun, and the RARE Champions of Hope Awards Ceremony and Dinner!
Summit sessions provide attendees with insights about the latest in rare disease innovations, best practices for advocating on an individual and organizational level, and actionable strategies to take home. This year, the Summit will be a hybrid event so all can attend – in person at the Town & Country Hotel in San Diego, California and live streamed online in our virtual event platform.
With over 20 CGTs projected to be approved by 2025, it’s clear that there are huge commercial and medical opportunities for precision medicine. But despite this unprecedented growth, unstable infrastructure, lack of standardization and novel scientific nuance means that there is still no industry blueprint for successful commercialization.
To realize this potential, precision medicine trailblazers must share lessons of launch success and overcome pain points to allow pharma to reinforce frameworks across manufacturing, market access and reimbursement to build infallible launch strategies across the board. Commercialization networks must go even further, transforming our healthcare system to guarantee scalable and sustainable growth.
Don’t get left behind.
Join us at Reuters Events: Cell and Gene Therapy USA where we have leaders from industry front runners to share their successes and pitfalls. With 30+ speakers, 5 case-studies and over 1500+ fellow CGT attendees - we will pioneer a new gold standard for commercialization, readying the world for CGT as a frontline treatment.
The International Society for Stem Cell Research (ISSCR) and the American Society for Gene and Cell Therapy (ASGCT) are partnering to host an exciting program on the latest advancements in regenerative medicine at the intersection of genetic and cellular technologies.
The marriage of genomic and cellular advances holds tremendous potential for regenerative medicine. Recent discoveries in stem cell biology are being combined with powerful new gene-editing technologies to bring about potentially transformative new therapies for diseases affecting a wide range of tissue and organ systems. This three day meeting will highlight groundbreaking work developing therapies for diseases of the nervous, hematopoietic, and muscle systems, diabetes, metabolic diseases, and cancer, and feature forward-looking new technologies shaping the future of the field.
Join us on 21 - 23 September 2022 when world-renowned scientists developing gene and cell therapies will converge at the Monona Terrace Community and Convention Center in Madison, WI, a city recognized for its seminal contributions to human stem cell research. Scientists, researchers, and industry leaders will present new discoveries at the leading edge of regenerative medicine.
This is a fascinating, exciting, and perplexing time for biotechnology. The industry delivered RNA vaccines to save countless lives during the pandemic and has created impressive early clinical results using CRISPR gene editing to treat patients with deadly genetic diseases. And yet the sector has been tarnished with safety concerns, drug failures, and lay-offs.
For more than 40 years, Genetic Engineering & Biotechnology News (GEN) has been covering the world of biotechnology. This September, we will cover it as never before – in a must-attend virtual event hosted by GEN Edge, the premium subscription news service of GEN.
THE STATE OF BIOTECH is an essential virtual summit (spanning two half days) featuring leaders from industry, academia, and finance discussing the latest critical breakthroughs, trends, and challenges in the biotech industry. The event will feature presentations and conversations with a trove of biotech leaders and entrepreneurs, brilliant scientists and innovators, and renowned analysts and commentators.
Gene Forum takes the honour to invite you to the International Human Gene Conference which will be held on September 26-28, 2022 at Melbourne Australia.
Over the past few years, Gene therapy has become a regular talk for the scientists and researchers from academia and industry all over the globe. Gene therapy is very huge and more team’s diverse research is needed to find the effective treatments and best possible ways to manage the rare diseases. With a great substantial research on genetics happening in this part of the world, therefore it has developed into a forum to discuss important challenges in this field.
The aim of the conference is to bring together all the key stakeholders interested in genetics and gene therapy to share and discuss advances and developments in these fields. Therefore we aimed at assisting academicians, business executives, researchers, scientists, manufacturers, gene therapy companies, communities, and agencies to keep on new developments in their specific fields and to join forces in finding alternative solutions.
It’s a unique way to approach and encourage a dialogue between speakers and delegates through its well-planned agenda with the series of talks, poster presentations, panel discussions and networking events that will keep participants engaged in learning. This will help rising scientific queries and provide solutions for a smarter and more advanced future.
We are stepping forward to create a platform to bring all the researchers from around the world and the research community to collaborate with the industries to focus on their efforts. The industry partners and attending experts will also provide a fantastic networking experience.
The World Molecular Imaging Congress brings together people from across the globe who represent the entire spectrum of Molecular Imaging. These individuals gather at WMIC to exchange ideas and foster innovation. The scientific and educational sessions are replete with leaders in the field and young scientists alike, each of whom has made significant contributions to our understanding of biology, advanced technology innovation, and/or evaluated new developments in the clinic. These sessions are complemented by thousands of abstracts that detail advances and highlight the latest developments in Molecular Imaging. Our industry exhibitors and sponsors showcase their innovations in the exhibition hall and lecture hall, detailing advances that will refine your animal models, accelerate your research, and improve clinical care. Each WMIC session is packed with innovative ideas and cutting-edge research. Molecular Imaging is a window into biology that enables discovery. We use these windows to investigate new biology and increase understanding, and the better we understand biological processes of living systems, with all of the contextual influences intact, the more effective our therapies will be in the clinic. Molecular Imaging lies at the heart of precision medicine. WMIC is the event that showcases all of the innovations in Molecular Imaging and shows the utility of novel imaging strategies in clinical investigation and the study of disease. Molecular Imaging as a field lies at the nexus of innovation in chemistry, hardware development, software innovation, biology, and medicine, and the WMIC is where you will hear about the most exciting highlights and the most in-depth evaluation. You will not want to miss WMIC 2022 in Miami!
The Oligonucleotide Therapeutics Society (OTS) Annual Meeting is a forum for the realization of the Society's mission and goals, to foster academic and industry-based research and development of oligonucleotide therapeutics. Leaders in the field from across the globe alongside students will present on an array of topics, including chemistry, AI/machine learning, genome & RNA editing, and preclinical and clinical research.
The Annual Meeting is open to anyone interested or involved in oligonucleotide therapeutics.